Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT.

Autor: Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. asureda@iconcologia.net., Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Bacigalupo A; Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Bhatt VR; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., de la Fuente J; Department of Paediatrics, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.; Department of Immunology & Inflammation, Imperial College London, London, UK., Ho A; Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore., Kean L; Stem Cell Transplantation Program. Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee JW; Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Sánchez-Ortega I; EBMT Medical officer, EBMT executive office, Barcelona, Spain., Savani BN; Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Schetelig J; Medical Department I, University Hospital Carl Gustav Carus. TU Dresden & DKMS Group, Clinical Trials Unit, Dresden, Germany., Stadtmauer EA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Takahashi Y; Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan., Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan., Koreth J; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Kröger N; Department for Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany., Ljungman P; Department. of Cellular Therapy and Allogeneic Stem Cell Transplantation. Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan., Popat U; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soiffer R; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Stefanski HE; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2024 Jun; Vol. 59 (6), pp. 832-837. Date of Electronic Publication: 2024 Mar 05.
DOI: 10.1038/s41409-024-02251-0
Abstrakt: Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism. To attempt broader international consensus, a panel of adult and pediatric physician transplant experts was assembled from European Society for Blood and Marrow Transplantation (EBMT), ASTCT, the Center for International Blood and Marrow Transplant Research (CIBMTR), and Asia-Pacific Blood and Marrow Transplantation (APBMT). Consensus was defined as ≥70% of voting members strongly agreeing or somewhat agreeing with a definition. With few exceptions, there was a consensus to endorse the prior ASTCT definitions. Importantly, we revised existing EBMT and CIBMTR data collection forms to align with these harmonized definitions that will facilitate research and international collaboration among transplant researchers and across transplant registries.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: